OVID Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
OVID is not a good buy right now for an impatient investor. Despite bullish longer-term moving averages and very supportive Wall Street targets, the near-term tape is soft (negative, expanding MACD histogram; price still below the 1.654 pivot), there are no near-term news catalysts, and hedge funds have been aggressively selling last quarter. I would wait for a clean move back above ~1.65 (pivot) with improving momentum before buying; at current ~$1.56 pre-market, it’s more of a hold/avoid than an immediate entry.
Pre-market price ~$1.56 (+0.65%) sits just above first support (S1=1.516) and below the pivot (1.654), implying the stock is still in a near-term ‘below-pivot’ posture. Trend structure is constructive on moving averages (SMA_5 > SMA_20 > SMA_200), which supports a bullish intermediate-term bias, but momentum is currently working against a fresh entry: MACD histogram is negative (-0.0113) and expanding bearishly, suggesting downside pressure is still building. RSI(6)=37.84 is not deeply oversold, so there’s room for more weakness without a technical ‘snap-back’ signal. Upside levels to reclaim: 1.654 first, then R1=1.791. Downside risk area: 1.516 then 1.431 if support breaks. Pattern-based projection also leans slightly negative near-term (higher odds of small declines next day/week), with a modest positive bias over the next month.
Strong analyst optimism focused on OV329 and the epilepsy opportunity (multiple Outperform/Buy initiations and raised targets).
Option market skew/flow is call-favored (low put/call ratios), suggesting traders lean bullish.
Longer-term trend structure is still constructive (bullish moving-average stack).
No news in the last week—no obvious near-term event-driven catalyst to reverse momentum quickly.
Momentum deterioration: MACD negative and worsening; price still below the key pivot (1.654).
Hedge funds are selling, with selling amount up ~668% QoQ—institutional pressure can cap rallies.
Short-term pattern probabilities lean slightly negative over the next day/week.
Latest quarter (2025/Q3): Revenue fell to $132K (-23.7% YoY). Net income was -$12.158M (loss), showing a -13.19% YoY deterioration. EPS was -$0.17 (-15% YoY). Gross margin is reported at 100% (typical for minimal revenue/biotech-type financial profiles), but overall the quarter reflects continued losses and no accelerating topline growth—fundamentals are not currently providing a near-term buying trigger.
Analyst trend is decisively positive recently: multiple initiations with Outperform/Buy ratings and targets of $3, $4, and $5, plus one price-target raise to $2 from $1.50 while maintaining Buy. Wall Street ‘pros’ view: PROS—OV329 seen as differentiated with favorable early safety, strong epilepsy market dynamics, and additional optionality from the KCC2 portfolio. CONS—these bullish views are thesis-driven and depend on clinical progress; near-term fundamentals remain loss-making and there’s no fresh news catalyst right now. Influential/political trading: no recent Congress trading data available; insider activity is described as neutral (no significant trend).
